论文部分内容阅读
从手术当日起，给２０例恶性肿瘤患者静脉点滴西米替丁（２０ｍｇ／ｋｇ·ｄ）。结果显示，西米替丁能升高辅助性／诱导性Ｔ细胞（ＣＤ４）和ＣＤ４／抑制性／细胞毒性Ｔ细胞（ＣＤ８），并降低ＣＤ８。用４０例患者术前血标本行体外实验，结果显示西米替丁能升高体外淋巴细胞转化试验（ＬＴＴ）和白细胞介素－２分泌细胞（ＩＬ－２ＳＣ）。表明西米替丁有免疫增强作用，可以用作恶性肿瘤的辅助治疗。
From the day of surgery, 20 patients with malignant tumors received cimetidine intravenously (20 mg/kg·d). The results showed that cimetidine increased helper/inducing T cells (CD4) and CD4/inhibitory/cytotoxic T cells (CD8) and reduced CD8. Preoperative blood samples from 40 patients were tested in vitro and the results showed that cimetidine increased the lymphocyte transformation test (LTT) and interleukin-2 secreting cells (IL-2SC) in vitro. It shows that cimetidine has an immunopotentiating effect and can be used as an adjuvant therapy for malignant tumors.